These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27990653)

  • 21. Synthesis and in vivo antitumor evaluation of an orally active potent phosphonamidate derivative targeting IDO1/IDO2/TDO.
    Feng X; Shen P; Wang Y; Li Z; Bian J
    Biochem Pharmacol; 2019 Oct; 168():214-223. PubMed ID: 31306643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase.
    Li Y; Zhang S; Wang R; Cui M; Liu W; Yang Q; Kuang C
    Bioorg Med Chem Lett; 2020 Jun; 30(11):127159. PubMed ID: 32247733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and biological evaluation of novel naphthoquinone derivatives as IDO1 inhibitors.
    Pan L; Zheng Q; Chen Y; Yang R; Yang Y; Li Z; Meng X
    Eur J Med Chem; 2018 Sep; 157():423-436. PubMed ID: 30103191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.
    Zhang Y; Hu Z; Zhang J; Ren C; Wang Y
    Eur J Med Chem; 2022 Aug; 238():114524. PubMed ID: 35696861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantification of IDO1 enzyme activity in normal and malignant tissues.
    Zhai L; Ladomersky E; Bell A; Dussold C; Cardoza K; Qian J; Lauing KL; Wainwright DA
    Methods Enzymol; 2019; 629():235-256. PubMed ID: 31727243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434).
    Doi T; Fujiwara Y; Shitara K; Shimizu T; Yonemori K; Matsubara N; Ohno I; Kogawa T; Naito Y; Leopold L; Munteanu M; Yatsuzuka N; Han SR; Samkari A; Yamamoto N
    Invest New Drugs; 2021 Feb; 39(1):152-162. PubMed ID: 32564277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation and comparison of the commonly used bioassays of human indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO).
    Zhang S; Guo L; Yang D; Xing Z; Li W; Kuang C; Yang Q
    Bioorg Chem; 2020 Nov; 104():104348. PubMed ID: 33142415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer.
    Chen B; Alvarado DM; Iticovici M; Kau NS; Park H; Parikh PJ; Thotala D; Ciorba MA
    Cancer Immunol Res; 2020 Apr; 8(4):451-464. PubMed ID: 32127391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
    Kim M; Tomek P
    Front Immunol; 2021; 12():636081. PubMed ID: 33708223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.
    Jung KH; LoRusso P; Burris H; Gordon M; Bang YJ; Hellmann MD; Cervantes A; Ochoa de Olza M; Marabelle A; Hodi FS; Ahn MJ; Emens LA; Barlesi F; Hamid O; Calvo E; McDermott D; Soliman H; Rhee I; Lin R; Pourmohamad T; Suchomel J; Tsuhako A; Morrissey K; Mahrus S; Morley R; Pirzkall A; Davis SL
    Clin Cancer Res; 2019 Jun; 25(11):3220-3228. PubMed ID: 30770348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor.
    Balog A; Lin TA; Maley D; Gullo-Brown J; Kandoussi EH; Zeng J; Hunt JT
    Mol Cancer Ther; 2021 Mar; 20(3):467-476. PubMed ID: 33298590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO).
    Pan S; Zhou Y; Wang Q; Wang Y; Tian C; Wang T; Huang L; Nan J; Li L; Yang S
    Eur J Med Chem; 2020 Dec; 207():112703. PubMed ID: 32871341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 4,6-Substituted-1H-Indazoles as potent IDO1/TDO dual inhibitors.
    Yang L; Chen Y; He J; Njoya EM; Chen J; Liu S; Xie C; Huang W; Wang F; Wang Z; Li Y; Qian S
    Bioorg Med Chem; 2019 Mar; 27(6):1087-1098. PubMed ID: 30773421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors.
    Naing A; Algazi AP; Falchook GS; Creelan BC; Powderly J; Rosen S; Barve M; Mettu NB; Triozzi PL; Hamm J; Zhou G; Walker C; Dong Z; Patel MR
    Cancer; 2023 Jan; 129(1):71-81. PubMed ID: 36309837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma.
    Sumitomo M; Takahara K; Zennami K; Nagakawa T; Maeda Y; Shiogama K; Yamamoto Y; Muto Y; Nukaya T; Takenaka M; Fukaya K; Ichino M; Sasaki H; Saito K; Shiroki R
    Cancer Sci; 2021 Mar; 112(3):1038-1047. PubMed ID: 33410234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
    Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
    Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway.
    Du L; Xing Z; Tao B; Li T; Yang D; Li W; Zheng Y; Kuang C; Yang Q
    Signal Transduct Target Ther; 2020 Feb; 5(1):10. PubMed ID: 32296044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer.
    Liang H; Li T; Fang X; Xing Z; Zhang S; Shi L; Li W; Guo L; Kuang C; Liu H; Yang Q
    Cancer Lett; 2021 Dec; 522():32-43. PubMed ID: 34520819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery and biological evaluation of tanshinone derivatives as potent dual inhibitors of indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase.
    Liu J; Ren J; Yang K; Chen S; Yang X; Zhao QS
    Eur J Med Chem; 2022 May; 235():114294. PubMed ID: 35358772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.
    Nayak-Kapoor A; Hao Z; Sadek R; Dobbins R; Marshall L; Vahanian NN; Jay Ramsey W; Kennedy E; Mautino MR; Link CJ; Lin RS; Royer-Joo S; Liang X; Salphati L; Morrissey KM; Mahrus S; McCall B; Pirzkall A; Munn DH; Janik JE; Khleif SN
    J Immunother Cancer; 2018 Jun; 6(1):61. PubMed ID: 29921320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.